LIFT-TB Milestones

LIFT-TB helps those suffering from drug-resistant TB and strengthens the health programs that treat them.

Milestone data updated August 2023

Programmatic Uptake Milestones

  • scale-up plans

    7 of 7 Countries

    established scale-up plans confirmed by National Tuberculosis Programs

  • placed orders

    7 of 7 Countries

    placed orders to procure pretomanid

  • programmatic use

    6 of 7 Countries

    implementing BPaL in programmatic use, partially or nationally

  • Patients Treated

    3 of 7 Countries

    updated national TB treatment guidelines

Operational Research Milestones

  • Regulatory Submissions

    7 of 7 Countries

    completed regulatory submissions

  • Philippines, Ukraine, and Uzbekistan

    achieved regulatory approval of pretomanid

  • Operational Research Programs

    575/485

    119% of the target number of patients were enrolled

  • Patients Treated

    7 of 7 Countries

    have completed enrollment of operational research studies

Capacity Building Milestones

  • 1,244 Health Professionals

    trained in LIFT-TB countries

  • 7 of 7 Countries

    performed clinical training

  • 6 of 6 Countries

    performed data management training

  • 7 of 7 Countries

    developed training materials

Country Dashboards

LIFT-TB partners are ensuring that patients with highly drug-resistant TB have access to short, simplified therapy. In doing so, they are also building capacity to respond to the disease at a health system level. These dashboards provide an overview of where each country stands.

Updated August 2023

  • Indonesia

    Indonesia

    Global rank in DR-TB burden: 4

    Patients enrolled: 87

    Target enrollment: 100

    Health professionals trained: 414

    Regulatory submission for pretomanid: Yes

    Regulatory approval of pretomanid: Yes

    Training materials developed: Yes

    Clinical training performed: Yes

    Data management training performed: Yes

    Completed enrollment in operational research: Yes

    National scale-up plan: Yes

    Pretomanid ordered: Yes

    Programmatic use underway: Yes

    National treatment guidelines updated: Yes

  • Kyrgyzstan

    Kyrgyzstan

    Global rank in DR-TB burden: 25

    Patients enrolled: 50

    Target enrollment: 50

    Health professionals trained: 191

    Regulatory submission for pretomanid: Yes

    Regulatory approval of pretomanid: Yes

    Training materials developed: Yes

    Clinical training performed: Yes

    Data management training performed: Yes

    Completed enrollment in operational research: Yes

    National scale-up plan: Yes

    Pretomanid ordered: Yes

    Programmatic use underway: Yes

    National treatment guidelines updated: Yes

  • Myanmar

    Myanmar

    Global rank in DR-TB burden: 11

    Patients enrolled: 98

    Target enrollment: 100

    Health professionals trained: 108

    Regulatory submission for pretomanid: Yes

    Regulatory approval of pretomanid: Yes

    Training materials developed: Yes

    Clinical training performed: Yes

    Data management training performed: Yes

    Completed enrollment in operational research: Yes

    National scale-up plan: Yes

    Pretomanid ordered: Yes

    Programmatic use underway: Yes

    National treatment guidelines updated: Yes

  • Philippines

    Philippines

    Global rank in DR-TB burden: 6

    Patients enrolled: 103

    Target enrollment: 100

    Health professionals trained: 333

    Regulatory submission for pretomanid: Yes

    Regulatory approval of pretomanid: Yes

    Training materials developed: Yes

    Clinical training performed: Yes

    Data management training performed: Yes

    Completed enrollment in operational research: Yes

    National scale-up plan: Yes

    Pretomanid ordered: Yes

    Programmatic use underway: Yes

    National treatment guidelines updated: Yes

  • Ukraine

    Ukraine

    Global rank in DR-TB burden: 8

    Patients enrolled: 153

    Target enrollment: 135

    Health professionals trained: data not available

    Regulatory submission for pretomanid: Yes

    Regulatory approval of pretomanid: Yes

    Training materials developed: Yes

    Clinical training performed: Yes

    Data management training performed: Yes

    Completed enrollment in operational research: Yes

    National scale-up plan: Yes

    Pretomanid ordered: Yes

    Programmatic use underway: Yes

    National treatment guidelines updated: Yes

  • Uzbekistan

    Uzbekistan

    Global rank in DR-TB burden: 14

    Patients enrolled: 43

    Target enrollment: 50

    Health professionals trained: 110

    Regulatory submission for pretomanid: Yes

    Regulatory approval of pretomanid: Yes

    Training materials developed: Yes

    Clinical training performed: Yes

    Data management training performed: Yes

    Completed enrollment in operational research: Yes

    National scale-up plan: Yes

    Pretomanid ordered: Yes

    Programmatic use underway: No

    National treatment guidelines updated: Yes

  • Vietnam

    Vietnam

    Global rank in DR-TB burden: 9

    Patients enrolled: 41

    Target enrollment: 100

    Health professionals trained: 88

    Regulatory submission for pretomanid: Yes

    Regulatory approval of pretomanid: Yes

    Training materials developed: Yes

    Clinical training performed: Yes

    Data management training performed: Yes

    Completed enrollment in operational research: Yes

    National scale-up plan: Yes

    Pretomanid ordered: Yes

    Programmatic use underway: No

    National treatment guidelines updated: Yes

Ensuring Global Access to BPaL

LIFT-TB is a key component of TB Alliance’s efforts to ensure that the BPaL regimen is accessible to all who need it. There are multiple pathways to access including regulatory approvals, a named patient access program, availability through the Stop TB Partnership’s Global Drug Facility, and operational research programs including LIFT-TB.

BPaL regimen

As of June 2023, pretomanid for use in the BPaL regimen has been:

  • Approved by 26 regulatory authorities, including the U.S. FDA and the European Medicines Agency (EMA)

  • WHO pre-qualified

  • Endorsed in WHO treatment guidelines for programmatic use in treating almost all forms of DR-TB

  • Administered through operational research programs in 14 countries

  • Available globally through Viatris’ Named Patient Access Program to patients in advance of national regulatory approvals

  • Listed in the Stop TB Partnership’s Global Drug Facility to ensure availability in 150 low- and middle-income counties

  • Procured by 70 countries

Visit www.tballiance.org for more information on pathways to access BPaL